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A Cross-Sectional, Observational Study Of High Override Rates Of Drug 
Allergy Alerts In Inpatient And Outpatient Settings and Opportunities for 
Improvement 
 
ABSTRACT  
 
Objectives: To evaluate how often and why providers overrode drug allergy alerts in 
both the inpatient and outpatient settings.  
Design: A cross-sectional, observational study of drug allergy alerts generated over a 
three-year period between Jan 1st, 2009, and Dec 31st, 2011. 
Setting: A 793-bed tertiary care teaching affiliate of Harvard Medical School and 36 
primary care practices. 
Participants: Drug allergy alerts were displayed for a total of 29,420 patients across 
both settings.  
Main outcome measures: Proportion of drug allergy alerts displayed and overridden, 
proportion of appropriate overrides, proportion of overrides in each medication class, 
different reasons for overriding, and types of reactions overridden. 
Results: A total of 158,023 drug allergy alerts were displayed, 131,615 (83%) in the 
inpatient setting and 26,408 (17%) in the outpatient setting; 128,157 (81%) of which 
were overridden. A random sample of inpatient (n=200, 0.19%) and outpatient (n=50, 
0.25%) alert overrides were screened for appropriateness, with over 96% considered 
appropriate. Alerts for some drug classes, such as ‘Non-antibiotic sulfonamides’, were 
overridden for more than 81% of prescriptions in both settings. The most common 
override reason was ‘patient has taken previously without allergic reaction’. In the 
  2 
inpatient setting alone, 70.9% of alerts that warned against the risk of ‘anaphylaxis’ 
were overridden. 
Conclusions: The information contained in patients’ drug allergy lists needs to be 
regularly updated. Most of the drug allergy alerts were overridden, with the majority 
of alert overrides in the sub-sample considered appropriate. Some of the rules for 
these alerts should be carefully reviewed and modified, or removed. Further research 
is needed to understand providers’ overriding of alerts that warned against the risk of 
‘anaphylaxis’, which are more concerning with respect to patient safety.  
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INTRODUCTION 
 
The prevalence of allergies is increasing not only in the U.K. but across the 
world, with as many as 30% of adults and 40% of children affected by allergies in the 
United States (U.S.).
1
 Drug allergies in particular are becoming increasingly common. 
It has been estimated that the drug penicillin is responsible for approximately 75% of 
fatal anaphylactic cases in the U.S., leading to 500 - 1,000 deaths per year.
2
  
Computerized physician order entry (CPOE) with clinical decision support 
(CDS) allows physicians to enter medication orders electronically and provides real 
time guidance and support to assist them with their prescribing.
3-6
 This guidance can 
take many different forms, including visual alerts or reminders about potential 
hazardous drug-drug or drug allergy interactions.
7,8
 However, the problem of alert-
fatigue has been well documented; prescribers are often exposed to too many alerts, 
which can result in them ignoring or failing to respond appropriately to even 
important alerts which can result in serious harm.
9,10
  
Drug allergy alerts differ from other types of medication-related alerts in that 
they are heavily dependent on patient recall rather than those that are dependent on 
discrete lab values, diagnoses, or known interactions with other drugs.
11
 In CPOE 
systems, prescribed drugs can be checked against the patient’s allergy list, and a drug 
allergy alert can warn the prescriber about a possible ‘drug allergy’. A ‘drug allergy’ 
is a type of unpredictable drug hypersensitivity reaction, which can be either 
immediate (immunoglobulin E (IgE)–mediated) or delayed (non–IgE-mediated).12 
These allergic reactions may often present with a broad range of symptoms, including 
prominent physical signs such as an itchy red skin rash (e.g., urticarial), nausea, 
vomiting or mental status changes. Drug-induced anaphylaxis is potentially fatal and 
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usually characterized by rapid-onset cardiovascular collapse. A number of studies 
have reported very high override rates of drug allergy alerts in primary care.
9,13
 
However, it is currently unclear which drug classes and types of reactions were highly 
overridden. Another study recently evaluated providers drug allergy alerts overrides 
in two U.S. hospitals.
14
 However, this study does not consider the appropriateness of 
providers’ drug allergy alert overrides, or how often specific drug classes were 
overridden in other clinical settings such as primary care.   
Another factor complicating safety is the existence of cross-sensitization. 
Once an individual has become sensitized to a drug, the possibility exists that the 
same individual may also react to drugs with a close structural chemical relationship 
or to immunochemically similar metabolites.
12
 Drug allergy alerts may be generated 
for possible cross-reactivity associations between drugs, such as penicillins and other 
antibiotics containing a beta-lactam ring e.g., cephalosporins, carbapenems, and 
monobactams.
15
 According to the World Allergic Organization, the range of cross-
sensitization varies greatly among individuals and is often difficult to predict with any 
certainty.
12
 In this study, we evaluated how often and more importantly why providers 
overrode drug allergy alerts in both the inpatient and outpatient settings. Specific 
outcomes were: (1) the appropriateness of providers’ drug allergy alert overrides, (2) 
proportion of overrides in each medication class, (3) the reasons why providers chose 
to override these alerts, and (4) the different types of reactions overridden.  
 
METHODS 
 
Research study site  
This study included data from the Brigham and Women's Hospital (Boston, 
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MA), a 793-bed tertiary care teaching affiliate of Harvard Medical School, and 36 
primary care practices. All these health organizations are part of a regional integrated 
healthcare delivery system, Partners HealthCare.  
 
Electronic Health Record (EHR) and Clinical Decision Support  
At the time of this study, all prescriber orders were entered through the 
Brigham Integrated Clinical Information System (BICS) at the Brigham and Women’s 
hospital, and the Longitudinal Medical Record (LMR) in the ambulatory care setting. 
The BICS and LMR provide clinical, administrative, and financial computing 
functions, which included patient-specific decision support usually presented to 
providers in the form of medication alerts at the time of prescribing. These included 
drug-allergy interaction alerts, which are triggered if the patient has a documented 
allergy or intolerance in their EHR to the prescribed product or drug agent. Drug 
allergy alert logic was initially sourced from the commercial knowledge base, First 
DataBank (First DataBank, Inc. South San Francisco, CA), and reviewed by an expert 
committee. In contrast to the Partners drug-drug interaction knowledge base, the drug 
allergy alert knowledge base has not been modified or iteratively improved over time 
to reduce the number of false positive alerts.  
 
When a drug allergy interaction alert is generated in either the inpatient or 
outpatient setting, a specific recommendation is presented to the physician, which is 
linked to a monograph. The alert message will indicate whether the patient has a 
‘definite’ (the drug being ordered is an exact match to the allergen e.g., penicillin 
documented in allergy list and penicillin ordered), ‘probable’ (the drug being ordered 
is in the same allergen group e.g., penicillin (penicillins) documented in allergy list 
and amoxicillin (penicillins) ordered), or ‘possible’ reaction (cross sensitivity is 
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considered likely e.g., penicillin (penicillins) documented in allergy list and 
cephalexin (cephalosporins) ordered), as well as the specific type of reaction that the 
patient may be at risk of developing e.g., hives, anaphylaxis (Figures 1 and 2).  
 
 
Figure 1. Screenshot of a drug allergy alert in the inpatient setting 
 
 
 
Figure 2. Screenshot of a drug allergy alert in the outpatient setting 
 
 
In the outpatient setting, the alert warning gives the provider the choice of 
selecting ‘patient does not have this allergy, will discontinue pre-existing allergy’ or 
overriding the alert. Should the physician choose to override the alert, they are 
required to select one of the following coded ‘override’ reasons in order to proceed: 
‘Patient has taken previously without allergic reaction’, ‘Low risk cross sensitivity, 
will monitor’, ‘No reasonable alternatives’, or ‘Other’ (Figure 2). If ‘Other’ is 
selected, further details should be entered in the free-text field. In the inpatient setting, 
the alert warning gives the provider the choice of cancelling the current order or 
keeping it, in which case they are required to enter a reason justifying their decision to 
override the alert in the free-text field provided (Figure 1). 
 
Study design and sample selection 
This study was a cross-sectional, observational study of drug allergy alerts 
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generated over a three-year period between January 1st, 2009, and December 31st, 
2011. The necessary approvals were obtained to access these data from the Partners 
Human Research Committee (PHRC), which is the Institutional Review Board (IRB) 
of Partners Research Management at Partners HealthCare. All drug allergy alerts 
triggered in the inpatient and outpatient settings during the study period were 
downloaded. This included patients’ names and medical record identification 
numbers; names of both the allergic reaction and medicine that triggered the drug 
allergy alert; date of alert; practice location (outpatients)/specialty (inpatients); and 
the reasons given by providers at the time of overriding the alert.  
 
Appropriateness check 
Alert overrides of drug allergy alerts were considered appropriate for new 
orders in the inpatient and outpatient settings if the reason indicated by the provider 
e.g., ‘patient does not have this allergy, will discontinue pre-existing allergy’, ‘low 
risk cross sensitivity, will monitor’, ‘no reasonable alternatives’, ‘patient has taken 
previously without allergic reaction’, or ‘other’ could be verified on chart review. For 
renewal orders, the patient’s chart was reviewed to confirm that there was no previous 
history that the patient had an allergic reaction to the drug (e.g., rash, hives, 
anaphylaxis, mental status change, nausea and vomiting) and the patient did not 
experience an adverse event after the medication was ordered for the patient.  
A pharmacist (D.L.S.) screened a random sample of inpatient (n=200, 0.19%) 
and outpatient (n=50, 0.25%) alert overrides for appropriateness. A second academic 
pharmacist (M.A.) independently reviewed the electronic inpatient medical charts (n= 
200), and inter-rater agreement comparing the appropriateness versus 
inappropriateness of each alert override was calculated and found to be excellent 
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(κ=0.76). An attending physician (K.C.N) and academic nurse (I.C.) independently 
reviewed the electronic outpatient medical charts (n=50), and inter-rater agreement 
was also found to be excellent (k=0.86). Any disagreements were resolved by 
discussion with another reviewer (D.W.B.). 
 
Data Analysis 
Data were processed using structured query language (SQL) statements. 
Natural language processing algorithms were developed to complete the 
categorizations of free-text override reasons in the outpatient setting and uncoded 
allergic reactions in both settings. For alerts that displayed more than one different 
type of allergic reactions, only the most severe reactions were considered. All drugs 
triggering allergy alerts were mapped to ATC codes (Anatomical Therapeutic 
Chemical Classification System, World Health Organization, Geneva, Switzerland) in 
order to enable grouping of drugs into drug classes. In the inpatient setting, a research 
assistant (N.M.) mapped each of the free-text entries given by providers to justify 
their decision to override the alert (n=20,699) to one of 30 individual categories. Each 
category contained a group of words or phrases with similar meaning or connotations, 
and included the coded reasons in the outpatient setting for comparison (e.g., ‘patient 
has taken previously without allergic reaction’ (Category 2), ‘low risk cross 
sensitivity, will monitor’ (Category 3), ‘no reasonable alternatives’ (Category 5)); 
further details can be found in Table 3. Words and phrases that could not be grouped 
were classified under ‘Other’ (Category 30). D.L.S provided a second check of this 
classification process. Descriptive statistics were computed using the software R, 
version 3.0.2 (R Foundation for Statistical Computing, Vienna, Austria). 
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RESULTS 
Summary  
A total of 158,023 drug allergy alerts were displayed, 131,615 (83%) in the 
inpatient setting and 26,408 (17%) in the outpatient setting, over the three-year time 
period; 128,157 (81%) of which were overridden. These alerts were displayed for a 
total of 29,420 patients across both settings. The drug classes ‘Opioids’, ‘Non-
antibiotic sulfonamides (without coxibs)’, which included drugs like furosemide 
(Lasix®) and indapamide (Lozol®), and ‘Non-antibiotic sulfonamides (coxibs)’, 
which included drugs like celecoxib (Celebrex®), were overridden over 81% of the 
time in both settings. The most common reason for overriding drug allergy alerts in 
both settings was ‘patient has taken previously without allergic reaction’. However, 
in a random sample of inpatient (n=200, 0.19%) and outpatient (n=50, 0.25%) alert 
overrides, over 96% (n=240) of alert overrides in both settings were considered 
appropriate. In the inpatient setting, 70.9% (n=1,682) of alerts that displayed 
‘anaphylaxis’ were overridden, compared to 56% (n=130) in the outpatient setting.  
 
Number, type and overrides of drug allergy alerts 
A total of 131,615 drug allergy alerts were displayed in the inpatient setting 
over the study time period. The provider indicated that the ‘patient did not have this 
allergy’ for 2% (n=2,602) of these alerts. The overall alert override rate was 81.9% 
(n=107,812) in the inpatient setting. Table 1 describes the top drug classes that were 
overridden. The override rate for monoclonal antibodies was 98.1% (n=51) and 
included for comparison with the top drug classes in Table 1. The number of alerts 
overridden in the drug class ‘Opioids’ was 87.2% (n=58,348) followed by the class 
‘Non-antibiotic sulfonamides (without coxibs)’ at 84.4% (n=514), and ‘Non-antibiotic 
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sulfonamides (coxibs)’ at 81.6% (n=129). The override rate for ‘Sulfonamide 
antibiotics’ was far lower than other sulfonamides (59.6%, n=627). The ‘Other drugs’ 
category contained individual drugs that were collectively overridden 74.5% 
(n=24,463); drug allergies triggered for the top five ‘other drugs’ included 
paracetamol (4.4%, n=4,375), metoprolol (1.6%, n=2,168), prochlorperazine (1.1%, 
n=1,444), simvastatin (0.9%, n=1,154), and rosuvastatin (0.6%, n=826). The drug 
class ‘Opioids’ generated the highest number of total orders in the study period and 
were the second highest class to trigger an alert; orders for non-antibiotic 
sulphonamides triggered the highest percentage of alerts.    
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Table 1. Top drug classes that were overridden in the inpatient setting 
Drug class 
Total No.  
Orders 
Alerts 
Triggered 
 
Percentage of orders 
that triggered an alert  
Alerts 
Overridden 
 
 
n n 
%  
(no. alerts / total 
no. alerts) 
%  
(no. alerts / total no. 
orders) 
n 
% 
(no. alerts / total no. 
alerts triggered) 
Monoclonal antibodies 1,276 52 0 4.1 51 98.1 
Opioids 428,074 66,949 50.9 15.6 58,348 87.2 
Non-antibiotic 
sulfonamides (without 
coxibs) 
152,286 609 0.5 0.4 514 84.4 
Non-antibiotic 
sulfonamides (coxibs) 
624 158 0.1 25.3 129 81.6 
Cephalosporins & other 
beta-lactams 
80,615 17,978 13.7 22.3 14,543 80.9 
Aspirin & NSAIDs* 
(without coxibs) 
139,069 8,730 6.6 6.3 6,809 78 
ACE inhibitors & 
angiotensin receptor 
blockers 
46,319 724 0.6 1.6 560 77.3 
Penicillins 26,999 2,379 1.8 8.8 1,679 70.6 
Sulfonamide antibiotics 12,536 1,052 0.8 8.4 627 59.6 
Contrast media 10,984 161 0.1 1.5 89 55.3 
Other drugs 4,471,594 32,823 24.9 0.7 24,463 74.5 
Total 5,370,376 131,615 100 2.45 107,812 81.9 
* = Non-steroidal anti-inflammatory drugs (NSAIDs) 
 = Angiotensin-converting-enzyme (ACE) inhibitors 
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In the outpatient setting, the number of drug allergy alerts displayed 
(n=26,408) was only a fifth of those displayed over the same time period in the 
inpatient setting (n=131,615). When compared to the total number of orders placed in 
both settings, drug allergy alerts were triggered less frequently in the outpatient 
setting (1.3%) than the inpatient setting (2.45%). The providers indicated that the 
‘patient did not have this allergy, will discontinue pre-existing allergy’ in over 5% 
(n=1,418) of cases. Overall alert override rate was statistically lower in the outpatient 
setting (77%, n=20,345), p<0.0001. Table 2 describes the top drug classes that were 
overridden in the outpatient setting. There was only one alert for monoclonal 
antibodies, which was not overridden. The alert override rate for ‘Non-antibiotic 
sulfonamides (coxibs)’ (87.2%, n=157) was higher than for ‘Non-antibiotic 
sulfonamides (without coxibs)’ (81.9%, n=521), which differed from the inpatient 
setting. The top five drugs triggered the most frequently in the ‘Other drugs’ category 
were pravastatin (4%, n=1,046), guaifenesin (3.8%, n=998), rosuvastatin (3.7%, 
n=983), azithromycin (3.1%, n=827), and simvastatin (3.1%, n=821); all drugs in this 
category were collectively overridden 79.3% (n=11,092). Similar to the inpatient 
setting, the drug class ‘Opioids’ also generated the highest number of total orders in 
the study period. Drug allergy alerts for this drug class were triggered less frequently 
in the outpatient setting (20.6%) than the inpatient setting (50.9%). The drug class 
‘Non-antibiotic Sulphonamides’ was also found to trigger the highest number of alerts 
per percentage of orders (10.67 %) in the outpatient setting. The percentage of orders 
for the drug class ‘Cephalosporins & other beta-lactams’ triggered a much higher 
number of alerts in the inpatient setting (22.3%) than the outpatient setting (8.8%). 
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Table 2. Top drug classes that were overridden in the outpatient setting 
 
Drug class 
Total No.  
Orders 
Alerts 
Triggered 
 
Percentage of orders that 
triggered an alert  
Alerts 
Overridden 
(n=107,812) 
 
n n 
%  
(no. alerts / total no. alerts) 
%  
(no. alerts / total no. orders) 
n % 
Non-antibiotic sulfonamides 
(coxibs) 
1,687 180 0.7 10.7 157 87.2 
Opioids 106,972 5,451 20.6 5.1 4,605 84.5 
Non-antibiotic sulfonamides 
(without coxibs) 
78,947 636 2.4 0.8 521 81.9 
Aspirin & NSAIDs* (without 
coxibs) 
89,590 2,443 9.3 2.7 1,827 74.8 
ACE inhibitors & 
angiotensin receptor blockers 
76,639 597 2.3 0.8 438 73.4 
Cephalosporins & other beta-
lactams 
15,933 1,400 5.3 8.8 1,009 72.1 
Penicillins 50,351 1,365 5.2 2.7 611 44.8 
Sulfonamide antibiotics 24,412 347 1.3 1.4 85 24.5 
Other drugs 1,550,659 13,988 53 0.9 11,092 79.3 
Monoclonal antibodies 340 1 0 0.3 0 0 
Contrast media 1 0 0 0 0 0 
Total 1,995,531 26,408 100.1 (rounded to 100) 1.3 20,345 77.0 
* = Non-steroidal anti-inflammatory drugs (NSAIDs) 
 = Angiotensin-converting-enzyme (ACE) inhibitors 
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Reasons for alert overrides  
In the inpatient setting, the most common free-text reason for overriding drug 
allergy alerts was ‘patient has taken previously without allergic reaction’ (Category 2, 
57.4%, n=61,858), followed by ‘physician aware’ (Category 7, 17.2%, n=18,583), 
and ‘low risk cross sensitivity, will monitor’ (Category 3, 12.3%, n=13,202) (Table 3). 
In 1,386 (1.3%) of cases, the provider commented that they were administering the 
drug as per the desensitization protocol (Category 17, 0.9%, n=927) or that they were 
“testing” or “trialing” the drug on the patient (Category 19, 0.4%, n=459). In 224 
(0.2%) of cases, the provider wrote that they would “administer slowly” (Category 11, 
0.1%, n=112), “discontinue the drug” (Category 12, 0.05%, n=57), “will discontinue 
if the patient experiences an adverse reaction” (Category 13, 0.03%, n=37), or 
“adjust dose” (Category 9, 0.02%, n=18). According to providers, the patient either 
explicitly requested the drug or agreed to the drug being prescribed in 46 cases 
(Category 28, 0.04%). 
Similarly in the outpatient setting, the most common coded reason given was 
‘patient has taken previously without allergic reaction’ (56.9%, n=11,594), followed 
by ‘low risk cross sensitivity, will monitor’ (27.9%, n=5,685), and ‘no reasonable 
alternatives’ (4.9%, n=986). Providers chose the coded reason ‘other’ in 10% 
(n=2,037) of cases (Table 3) and typed the free-text reason “OK” (indicating that the 
prescriber understood the alert) in 0.1% (n=20) of cases. In the outpatient setting, a far 
lower number of providers commented “physician aware” (0.11%, n=23), that they 
were administering the drug as per the desensitization protocol (0.08%, n=17) or that 
they were “testing” or “trialing” the drug on the patient (0.07%, n=14). Almost the 
same percentage of providers in the outpatients setting as in the inpatient setting 
stated that they would “discontinue the drug” (0.04%, n=8) or “discontinue if the 
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patient experiences an adverse reaction” (0.03%, n=7).  
 
Table 3. Reasons given by providers for overriding drug allergy alerts  
Override reasons given by provider Inpatient 
Category* 
Inpatients Outpatients 
 
N (%) N (%) 
Patient has taken previously without allergic  
reaction / patient has tolerated previously 
2 61,858 (57.4) 11,594 (56.9) 
Low risk cross sensitivity, will monitor  3 13,202 (12.3) 5,685 (27.9) 
No reasonable alternative / needed 5 1,664 (1.5) 986 (4.9) 
Other (free-text reason provided)  30 9,084 (8.4) 2,037 (10) 
Physician aware (free text reason) 7 18,583 (17.2) 23 (0.1) 
OK (free-text reason) 15 3,421 (3.17) 20 (0.1) 
Total   107,812  20,345  
* Examples of the individual categories, which each of the free-text entries given by 
inpatient providers were mapped to. 
 
Appropriateness of alert overrides 
In the inpatient setting, 96.5% (193/200) of the chart-reviewed alert overrides 
were judged to be appropriate on first review. Of the 193 alerts that were overridden 
appropriately, three displayed the reaction ‘anaphylaxis’. Of the seven specific alert 
overrides that were considered by the two independent reviewers to have been 
possibly inappropriately overridden, three were discussed with a third reviewer 
(D.W.B) before reaching final agreement; an inadequate explanation was provided in 
the free-text field for one of these overrides, and reviewers were unable to verify on 
chart review whether the patient received the drug and had an allergic reaction for a 
second of these overrides. Consensus was reached that a total of seven alert overrides 
were judged to be inappropriate in the inpatient setting. 
In the outpatient setting, 94% (47/50) of alert overrides were considered 
appropriate. Three specific alert overrides were discussed with a third reviewer 
(D.L.S) before reaching final agreement; in each of these cases, the provider chose the 
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reason ‘other’ and provided no free-text explanation; the third reviewer was unable to 
verify on chart review whether the patient had received the drug already without 
having an allergic reaction. Consensus was reached that a total of three alert overrides 
were judged to be inappropriate in the outpatient setting. 
 
Types of reactions 
The most common type of reaction displayed in the alert warnings in the 
inpatient setting related to the skin (27.4% of the total), which included rash (14.6%, 
n=19,172), hives (7.1%, n=9,353), and itching (5.7%, n=7,547). Over 21% of alerts 
(n=27,650) indicated some kind of gastro-intestinal upset and were overridden in 
85.3% (n=23,599) of cases. Table 4 describes the top 10 reactions that were displayed 
to providers and the override rates of these specific types of potential reactions. The 
percentages shown in Columns 2 and 4 show the fraction of how many alerts warned 
against the risk of the respective reaction in the Inpatient and Outpatient Settings, 
respectively. The percentages shown in the Columns 3 and 5 present the fraction of 
how many of the respective alerts were overridden by the providers in the Inpatient 
and Outpatient Settings, respectively. The number of alerts that displayed ‘shortness 
of breath’ and ‘anaphylaxis’ in the Inpatient Setting was 2,541 (1.9%) and 2,373 
(1.8%) respectively, and these were overridden in 81.2% (n=2,063) and 70.9% 
(n=1,682) of cases.  
In the outpatient setting, over 22.8% of alerts (n=6,009) displayed gastro-
intestinal upset and 81.9% (n=4,902) of these were overridden. Skin reactions were 
also commonly displayed (19.6%, n=5,167); these included rash (11.2%, n=2,956), 
hives (5.1%, n=1,353), and itching (3.2%, n=858), and were overridden on average 
66% (n=3,413). The number of alerts that displayed ‘shortness of breath’ and 
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‘anaphylaxis’ was far lower in the outpatient setting and overridden much less 70.8% 
(n=289) and 56% (n=130), respectively. 
 
Table 4. Top 10 reactions displayed to providers and the override rates of these 
specific types of potential reactions  
Reactions 
No. (%) of 
Inpatient  
alerts  
No. (%) of 
Inpatient 
overrides 
No. (%) of 
Outpatient  
alerts  
No. (%) of 
Outpatient 
overrides 
Unknown 29,125 (22.1) 23,745 (81.5) 3,031 (11.5) 2,038 (67.2) 
Gastro-intestinal 
upset 
27,650 (21) 23,599 (85.3) 6,009 (22.8) 4,902 (81.6) 
Rash 19,172 (14.6) 15,659 (81.7) 2,956 (11.2) 1,868 (63.2) 
Hives 9,353 (7.1) 7,539 (80.6) 1,353 (5.1) 906 (67) 
Itching 7,547 (5.7) 6,430 (85.2) 858 (3.2) 639 (74.5) 
Mental status change 6,685 (5.1) 5,610 (83.9) 924 (3.5) 765 (82.8) 
Angioedema 4,173 (3.2) 3,136 (75.1) 913 (3.5) 613 (67.1) 
Shortness of breath 2,541 (1.9) 2,063 (81.2) 408 (1.5) 289 (70.8) 
Anaphylaxis 2,373 (1.8) 1,682 (70.9) 232 (0.9) 130 (56) 
Myalgia 2,195 (1.7) 1,891 (86.2) 2,224 (8.4) 1,998 (89.8) 
Total 110,814 (84.2) 91,354 (82.4) 18,908 (71.6) 14,148 (74.8) 
 
 
DISCUSSION 
Over the last 20 years, there has been an increase in the drug allergy alert 
override rate at this hospital from about 50% in 1995,
16
 to 81.9% (inpatients) and 77% 
(outpatients) as found in this study. These high override rates are similar to those of 
previous studies which analyzed orders from the same and different hospitals,
16-18
 
although a little lower than the 91% override rate found by Weingart et al. in the 
outpatient setting.
13
 Over 96% of the chart-reviewed alert overrides in this study were 
judged to be appropriate. Overall, these data suggest that better documentation and 
  18 
updating of allergy records are needed in patient’s health records to ensure that these 
are correct and up-to-date, and further studies are needed to improve the sensitivity 
and specificity of allergy alerts, thus helping to specify which alerts should be turned 
on and which should be turned off. 
A few classes of drug accounted for a large proportion of this high drug 
allergy override rate, suggesting it could be readily addressed. Opiates in particular 
were one of the most frequently ordered and overridden drug classes, similar to other 
studies.
11,17
 A random sample of alert overrides in both settings were reviewed and 
over 94% were considered appropriate. Cross-reactivity in particular is an issue; many 
patients have a reaction to one opiate but it is not clear whether providers need 
additional warnings when others are given. Hsieh et al also reviewed the charts of a 
random subset of patients and found that none of the adverse drug events attributed to 
the overridden drug alert were preventable.
17
 The authors concluded that clinical need 
for the drug outweighed the risk of a serious allergic reaction, thus the drug allergy 
alert overrides were deemed clinically justifiable. 
Providers must ensure that patient self-reported allergies or intolerances are 
documented correctly in the electronic patient record and frequently updated. Many 
different types of providers can usually enter this information into the system at the 
time of the patient’s visit.13 Hseih et al. found that the degree of completeness of 
patients’ allergy lists was generally poor in the CPOE system.17 The accuracy of the 
information included in these lists was also questionable, and it was often unclear 
whether the specific reactions were IgE or non–IgE-mediated. Often, opioid side 
effects are recorded as allergies.
11
 This is because the reporting of allergies and 
intolerance and adverse effects are handled through the same mechanism.  This may 
be acceptable, but applications should ask providers to distinguish between them 
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when they are being reported. Hsieh et al also found that nausea and vomiting, which 
are not true IgE-mediated reactions, were the most common adverse drug reactions 
documented to narcotics in the patient’s allergy list.17 Further, in our study, the 
provider indicated that the patient (for whom a drug-allergy alert was triggered) did 
not actually have the allergy in 4,020 (2.5%) of cases. Providers overrode more than 
half of all drug allergy alerts giving the reason that the ‘patient has taken previously 
without allergic reaction,’ with the scenario most often being that the patient had an 
allergy recorded to a drug but the patient was taking it without difficulty. Similar 
findings were reported in another study conducted in the inpatient setting with 
providers choosing the same reason (49%) when overriding drug allergy alerts.
19
 On 
selecting this override reason, it should be possible to encourage providers to 
deactivate allergies by providing an automatic link for providers to update the drug 
allergy list.  Additional studies are also needed to look at the more efficient 
knowledge management of the drug allergy databases. 
One of the most common override reasons given in both settings was ‘low risk 
cross sensitivity, will monitor’. Previous studies have revealed how the majority of 
drug allergy overrides (90%) occurred when the allergen and drug belong to the same 
family but were not identical (e.g., codeine and hydromorphone).
17
 For some of the 
non-exact drug allergy matches presented in the study by Hsieh et al., the likelihood 
of an adverse reaction occurring to the patient on administration of the drug was felt 
to be extremely low. For example, the drug classes ‘non-antibiotic sulfonamides’ 
were overridden over 81% of the time in both inpatient and outpatient settings. Strom 
et al. conducted a retrospective cohort study examining patients who previously had 
an allergic reaction to a sulfonamide antibiotic and found that less than 10% of these 
patients had an allergic reaction to a sulfonamide non-antibiotic (e.g., celecoxib).
20 
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The authors concluded that this association appeared to be due to a predisposition to 
allergic reactions in general rather than to cross-reactivity with sulfonamide-based 
drugs. In other words, these patients were no more likely to have a subsequent 
hypersensitivity reaction to a drug containing a sulfonamide functional group (e.g., 
furosemide) than to a drug that did not (e.g., penicillin).
20
 This highlights the 
importance of incorporating clinical evidence on drug cross-reactivity into the 
decision support system, rather than relying on pharmacologic or structural 
similarity.
21
 
Over 70% of the drug allergy alerts that displayed the reaction ‘anaphylaxis’ 
in this study were overridden. This is a worrying finding, as a true allergic reaction 
severe enough to cause anaphylaxis will most often occur within minutes or hours of 
exposure. It is unclear from our study whether any of these patients (for whom an 
alert was triggered) had previously experienced such a reaction, or went on to 
experience any adverse events as a result of taking the prescribed drug (beyond the 
scope of this study). Identification of patients with a previous history of anaphylaxis is 
important, as over one third of these patients could suffer a serious recurrence.
22
 
However, with recent figures suggesting that the rate of anaphylaxis hospitalizations 
is on the rise in both the U.K. and U.S.,
23,24
 further research is needed to explore why 
providers chose to override these alerts. In the inpatient setting, Topaz et al reported 
how only about one-tenth of the alerts for potentially life threatening reactions (e.g., 
anaphylaxis) were based on an exact match between the allergy and prescribed drug, 
while the rest were based on either the cross-sensitivity or allergy group.
14
 These 
findings further suggest that patients’ medical records may contain inaccurate allergy 
information or the clinical evidence on drug cross-reactivity may need to be updated. 
This may be of particular importance to pediatric patient populations whose drug 
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allergy prevalence varies substantially from adults.
25
 
This study was undertaken within a single healthcare delivery system using 
two different homegrown prescribing systems (BICS and LMR) and, as such, is 
difficult to assess how generalizable the results are to other sites. However, our 
proportions are comparable with the results from different sites published by other 
research groups. The random sample of alert overrides reviewed for appropriateness 
was small compared with the total number of alerts triggered, and the accuracy of this 
review was reliant on the completeness of information contained in the patients’ 
charts. We did not control for the possibility that some alerts may have been repeated 
for the same patient. This paper presents the reasons why providers chose to override 
drug allergy alerts. Although providers in the inpatient setting enter this reason in the 
free-text field provided, providers in the outpatient setting selected one of the coded 
reasons provided. Notwithstanding these limitations, we believe that our findings have 
important implications for allergy alerting in other systems.  
 
 
CONCLUSION 
 
 
Drug allergy alerts are one of the most frequently displayed alerts in CPOE 
systems. There is little evidence, however, regarding the efficacy of these alerts. Most 
of the drug allergy alerts in this study were overridden, with over 94% of a sub-
sample of alert overrides considered appropriate. Some of the rules for these alerts 
should be carefully reviewed and modified, or removed. It is very important that the 
information contained in patients’ drug allergy lists is correct and up to date, and 
clinicians are encouraged to deactivate allergies by providing them with an automatic 
link to update their patients’ drug allergy lists.  The clinical evidence on drug cross-
reactivity in the decision support systems should be updated. Finally, we found that 
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providers overrode the majority of drug allergy alerts, including those that warned 
against the risk of ‘anaphylaxis’. More needs to be done to understand providers’ 
reasoning in overriding such alerts and reduce the possible threat to patient safety.  
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